HLS Therapeutics (TSX:HLS) Dividends Received


TSX:HLS HLS Therapeutics Inc TSX:HLS
67 GF Score
Price C$4.30
GF Value C$4.51
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TSX:HLS
67GF Score
HLS Therapeutics Inc TSX:HLS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.30 is trading 4.7% below its estimated GF Value™ of C$4.51. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Dividends Received:
  • GF Value™: C$4.51 vs. price of C$4.30 (4.7% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
67GF Score

Get the complete analysis for TSX:HLS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.30
Price
C$4.51
GF Value